Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green identify specific sessions and presentations they believe will bring the greatest enlightenment around tough challenges and unaddressed issues in Fatty Liver disease.
Joern Schattenberg joins the Surfers to identify exciting presentations and sessions from the Digital ILC 2021 meeting.
Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI’s US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, the group considers systems issues ranging from commitment to multi-disciplinary approaches to including Fatty Liver metrics in metrics like HEDIS in terms of their ability to focus needed care and attention on NAFLD and NASH.Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI’s US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, the group considers systems issues ranging from commitment to multi-disciplinary approaches to including Fatty Liver metrics in metrics like HEDIS in terms of their ability to focus needed care and attention on NAFLD and NASH.
Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI’s US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, the group discusses the need for common, reliable non-invasive diagnostic tests and education for providers on which tests they should rely on (HINT: not the ones most HCPs are using today!)
Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI’s US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, Andrew discusses the genesis of the US NASH Action Plan and the group begins to discuss education and awareness opportunities.
Global Liver Institute Director of Global Policy Andrew Scott walks a diverse set of stakeholders through the US NASH Action Plan, with special focus on education, awareness and clarity in diagnosis and treatment.
EASL Scientific Committee member Luca Valenti joins the Surfers to “crystal ball” potential key outcomes from Digital ILC 2021.
EASL Scientific Committee member Luca Valenti joins the Surfers to discuss some of the issues that will be discussed at Digital ILC 2021.
Stephen Harrison and EASL Scientific Committee member Luca Valenti Preview Highlights of the Digital ILC 2021.
EASL Scientific Organizing Committee member Prof. Luca Valenti joins the Surfers to discuss some of the major NAFLD-related topics we will learn more about at Digital ILC 2021.
Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. This conversation takes a deeper look at NASH Day and also Global Liver Institute’s growth and future plans.
Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. This conversation provides and overview of the day’s event.
Roger Green narrates a series of interviews, conversations and viewpoints about NGM Biopharmaceuticals discontinuing its F2/F3 aldafermin program
Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. Last year’s IND had 100+ participants. This year will be bigger! Learn why.
Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therapy after current Phase 2b and Phase 3 candidates have been approved. This conversation considers how the idea that front-line treaters will be PCPs might affect treatment patterns.
Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation examines the prospect for different kinds of backbone strategies.
Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation lays out basic premises.
Mazen Noureddin joins the Surfers to explore the issues and needs that will shape treatment guidelines in a world after NASH drugs come to market.
Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gawrieh to discuss why this epidemiology paper from the 2021 Journal of Hepatology is an urgent call to action for NAFLD and NASH screening and treatment.
Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gawrieh in a deeper dive into key findings from the 2021 Journal of Hepatology paper titled “Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.”
Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gawrieh share key findings from their 2021 Journal of Hepatology paper titled “Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.”
Study co-authors Stephen Harrison, Naim Alkhouri and Samer Gawrieh suggest that current estimates of NAFLD and NASH populations in the US may be meaningfully understated.
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This conversation is organized around competing strategies for diagnostic testing as the NASH market evolves.
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This conversation is organized around adoption of non-invasive testing in clinical development and when drugs will come to market.
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This conversation is organized around changes in treatment paradigms and guidelines.
